Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Journal
The New England journal of medicine
Journal Volume
386
Journal Issue
5
Date Issued
2022-02-03
Author(s)
Doki, Yuichiro
Ajani, Jaffer A
Kato, Ken
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria I
Holtved, Eva
Ostoich, Sandra A
Kim, Hye R
Ueno, Masaki
Mansoor, Wasat
Yang, Wen-Chi
Liu, Tianshu
Bridgewater, John
Makino, Tomoki
Xynos, Ioannis
Liu, Xuan
Lei, Ming
Kondo, Kaoru
Patel, Apurva
Gricar, Joseph
Chau, Ian
Kitagawa, Yuko
Abstract
First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma.
SDGs
Type
journal article